Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Intellia, Novartis form five-year CRISPR/Cas9 collaboration

Executive Summary

Over the next five years, Intellia Therapeutics Inc. and Novartis AG’s Novartis Institutes for BioMedical Research Inc. agreed to apply CRISPR/Cas9 gene editing and repair technologies ex vivo to chimeric antigen receptor T (CART) cells and hematopoietic stem cells (HSCs) for the treatment of cancers and hematological disorders.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies